Institutional implementation of clinical tumor profiling on an unselected cancer population.

BACKGROUND. Comprehensive genomic profiling of a patient's cancer can be used to diagnose, monitor, and recommend treatment. Clinical implementation of tumor profiling in an enterprise-wide, unselected cancer patient population has yet to be reported. METHODS. We deployed a hybrid-capture and massively parallel sequencing assay (OncoPanel) for all adult and pediatric patients at our combined cancer centers. Results were categorized by pathologists based on actionability. We report the results for the first 3,727 patients tested. RESULTS. Our cohort consists of cancer patients unrestricted by disease site or stage. Across all consented patients, half had sufficient and available (>20% tumor) material for profiling; once specimens were received in the laboratory for pathology review, 73% were scored as adequate for genomic testing. When sufficient DNA was obtained, OncoPanel yielded a result in 96% of cases. 73% of patients harbored an actionable or informative alteration; only 19% of these represented a current standard of care for therapeutic stratification. The findings recapitulate those of previous studies of common cancers but also identify alterations, including in AXL and EGFR, associated with response to targeted therapies. In rare cancers, potentially actionable alterations suggest the utility of a "cancer-agnostic" approach in genomic profiling. Retrospective analyses uncovered contextual genomic features that may inform therapeutic response and examples where diagnoses revised by genomic profiling markedly changed clinical management. CONCLUSIONS. Broad sequencing-based testing deployed across an unselected cancer cohort is feasible. Genomic results may alter management in diverse scenarios; however, additional barriers must be overcome to enable precision cancer medicine on a large scale. FUNDING. This work was supported by DFCI, BWH, and the National Cancer Institute (5R33CA155554 and 5K23CA157631).

[1]  Jürg Zimmermann,et al.  Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells , 1996, Nature Medicine.

[2]  Steven A. Roberts,et al.  Mutational heterogeneity in cancer and the search for new cancer-associated genes , 2013 .

[3]  Jae Cheol Lee,et al.  Activation of the AXL Kinase Causes Resistance to EGFR-Targeted Therapy in Lung Cancer , 2012, Nature Genetics.

[4]  S. Gabriel,et al.  Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. , 2014, Cancer discovery.

[5]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[6]  P. Hammerman,et al.  Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma , 2016, Clinical Cancer Research.

[7]  Michael Bittner,et al.  Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Levi A Garraway,et al.  Genomics-driven oncology: framework for an emerging paradigm. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  C. Sander,et al.  Genome Sequencing Identifies a Basis for Everolimus Sensitivity , 2012, Science.

[10]  W. Hahn,et al.  Prospective enterprise-level molecular genotyping of a cohort of cancer patients. , 2014, The Journal of molecular diagnostics : JMD.

[11]  John D Pfeifer,et al.  Detection of FLT3 internal tandem duplication in targeted, short-read-length, next-generation sequencing data. , 2013, The Journal of molecular diagnostics : JMD.

[12]  P. Jänne,et al.  MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Amber M. Johnson,et al.  Clinical next generation sequencing to identify actionable aberrations in a phase I program , 2014, Oncotarget.

[14]  Jae Cheol Lee,et al.  MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation. , 2014, Cancer research.

[15]  P. D. Dal Cin,et al.  Ewing sarcoma mimicking atypical carcinoid tumor: detection of unexpected genomic alterations demonstrates the use of next generation sequencing as a diagnostic tool. , 2014, Cancer genetics.

[16]  M. Ladanyi,et al.  Broad, Hybrid Capture–Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches , 2015, Clinical Cancer Research.

[17]  E. Petricoin,et al.  A pilot study utilizing multi-omic molecular profiling to find potential targets and select individualized treatments for patients with previously treated metastatic breast cancer , 2014, Breast Cancer Research and Treatment.

[18]  Funda Meric-Bernstam,et al.  Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  A. Redig,et al.  Clinical and Molecular Characteristics of NF1-Mutant Lung Cancer , 2015, Clinical Cancer Research.

[20]  P. Jänne,et al.  Clinical Implications of Variant ALK FISH Rearrangement Patterns , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[21]  Nikhil Wagle,et al.  High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. , 2012, Cancer discovery.

[22]  Lisle E. Mose,et al.  Germline Analysis from Tumor–Germline Sequencing Dyads to Identify Clinically Actionable Secondary Findings , 2016, Clinical Cancer Research.

[23]  Razelle Kurzrock,et al.  Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative , 2012, Clinical Cancer Research.

[24]  B. Crompton,et al.  Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) Study. , 2016, JAMA oncology.

[25]  Dennis C. Friedrich,et al.  Whole-exome sequencing and clinical interpretation of formalin-fixed , paraffin-embedded tumor samples to guide precision cancer medicine , 2014 .

[26]  Geoffrey R. Oxnard,et al.  Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer , 2013, Science Translational Medicine.

[27]  M. Kris,et al.  Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Mark D. Johnson,et al.  Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. , 2015, Neuro-oncology.

[29]  N. Robert,et al.  Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  G. Shapiro,et al.  Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  R. Kurzrock,et al.  On the Road to Precision Cancer Medicine: Analysis of Genomic Biomarker Actionability in 439 Patients , 2015, Molecular Cancer Therapeutics.

[32]  Nikhil Wagle,et al.  The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine , 2016, Genome Medicine.

[33]  William Pao,et al.  Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. , 2014, JAMA.

[34]  Theresa Zhang,et al.  Personalized genomic analyses for cancer mutation discovery and interpretation , 2015, Science Translational Medicine.

[35]  P. D. Dal Cin,et al.  Refractory myeloid sarcoma with a FIP1L1-PDGFRA rearrangement detected by clinical high throughput somatic sequencing , 2015, Experimental Hematology & Oncology.

[36]  A. D. Van den Abbeele,et al.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.

[37]  Vladimir Vacic,et al.  Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response. , 2015, JAMA oncology.

[38]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[39]  L. Macconaill,et al.  KRAS and NKX2‐1 Mutations in Invasive Mucinous Adenocarcinoma of the Lung , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[40]  William Pao,et al.  Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. , 2014, The oncologist.

[41]  Jane C Weeks,et al.  Physicians' attitudes about multiplex tumor genomic testing. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  M. Berger,et al.  Detecting somatic genetic alterations in tumor specimens by exon capture and massively parallel sequencing. , 2013, Journal of visualized experiments : JoVE.

[43]  L. Byers,et al.  Axl Receptor Axis: A New Therapeutic Target in Lung Cancer , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[44]  Nicolas Servant,et al.  Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. , 2015, The Lancet. Oncology.

[45]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[46]  P. D. Dal Cin,et al.  Detection of activating MAP2K1 mutations in atypical hairy cell leukemia and hairy cell leukemia variant , 2017, Leukemia & lymphoma.

[47]  P. Jänne,et al.  Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2. , 2015, Cancer research.

[48]  Udayan Guha,et al.  Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  T. Mok,et al.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.

[50]  Vladimir Vacic,et al.  Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions , 2014, Genome Biology.

[51]  Funda Meric-Bernstam,et al.  Building a personalized medicine infrastructure at a major cancer center. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  Donavan T. Cheng,et al.  Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. , 2015, The Journal of molecular diagnostics : JMD.

[53]  M. Mihm,et al.  Targeted next-generation sequencing reveals high frequency of mutations in epigenetic regulators across treatment-naïve patient melanomas , 2015, Clinical Epigenetics.

[54]  Alex M. Fichtenholtz,et al.  Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing , 2013, Nature Biotechnology.